The FDA lifted a clinical hold on the Phase II ROCKET clinical trial for Juno's lead CAR-T therapy candidate JCAR015 less than a week after it was instituted, allowing the company to proceed without using fludarabine in a pre-conditioning chemotherapy regimen.
Juno Therapeutics Inc. soared in after-hours trading on July 12 following the company's late-day announcement that a clinical hold on its Phase II ROCKET clinical trial for the chimeric antigen receptor T-cell (CAR-T) therapy JCAR015 has been lifted just a few business days after the US FDA instituted the hold in response to three deaths in the study.
Seattle, Washington-based Juno fell more than 27% after the stock market closed on July 7 when the company first revealed...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400)
